Federal Circuit applies Nautilus reasonable certainty rule

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Federal Circuit applies Nautilus reasonable certainty rule

Biosig’s patent survives despite the earlier setback from the Supreme Court

Yesterday, the Federal Circuit found that Biosig’s patent for a heart rate monitor associated with exercise equipment was not invalid.

The defendant Nautilus had argued that the patent was invalid due to indefiniteness. The case reached the Supreme Court, which rejected the Federal Circuit’s “insolubly ambiguous” test. Justice Ginsburg’s written decision instead provided another test for indefiniteness, stating that “a patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention”.

On remand, the Federal Circuit held that Biosig’s patent was not indefinite even under the new test. Nautilus argued that the term used in the patent referring to “a spaced relationship” between electrodes in the invention is legally indefinite because “the original intrinsic evidence point[s] in two opposite directions, leaving the claims’ boundaries—and thus the potential avenues for follow-on innovation—fundamentally uncertain”.

The Federal Court disagreed. It noted that the Supreme Court’s Nautilus ruling did not hold that terms of degree such as “a spaced relationship” were by definition legally indefinite, just that the patent must provide some standard to measure that degree.

Specifically, it referred back to its previous decision in this case, noting that “an ordinarily skilled artisan would be able to determine this language requires the spaced relationship to be neither infinitesimally small nor greater than the width of a user’s hands”. Furthermore, it said that, looking at the prosecution history, a person skilled in the arts would understand that the spaced relationship “as pertaining to the function of substantially removing EMG signals”, an important part of the invention.

Not so new?

The Federal Circuit also found that despite the Supreme Court directing the lower courts to apply the reasonable certainty standard for indefiniteness, the test is in fact not new. Biosig actually made a similar argument in its briefs and that courts have long held terms such as the ones used in the patent in question to be sufficiently definite. In fact, some observers such as Jason Rantanen of the University of Iowa predicted last month on Patently-O that the test laid out by the Supreme Court in Nautilus would not have much practical effect.

Similarly, Biosig’s counsel argued after the Supreme Court decision that despite the order directing the Federal Circuit to reconsider its patent for indefiniteness, the Supreme Court actually adopted the test that Biosig had argued for.

Judges Newman, Schall, and Wallach sat on the case. Mark David Harris of Proskauer Rose argued for Biosig while John Vandenberg of Klarquist Sparkman represented Nautilus.

more from across site and SHARED ros bottom lb

More from across our site

In-house counsel explain why firms should provide risk management advice that helps them achieve their goals
Attorneys at four firms explain the AI trends they expect in the future, including a potential shift in who plaintiffs sue for copyright infringement
The dispute at the Intellectual Property Enterprise Court pits Dryrobe against D-Robe and will include a ‘genericide’ element
Novo Nordisk losing patent rights covering Ozempic in Canada and a US Supreme Court decision favouring Ed Sheeran were also among the top talking points
The court will hand down its ruling in Iconix v Dream Pairs on Tuesday, June 24, in a case that concerns post-sale confusion
Developments included a stay in a row concerning the UPC’s jurisdiction and a timeline for the rollout of the long-awaited new CMS
Jorg Thomaier, who has been head of IP at the German pharma company since 2010, will leave later this year and hand the reins to the company’s head of patents
Companies must conduct thorough IP due diligence – even if it may not be mandatory
Celia Cheah at Wong & Partners in Malaysia says she is aiming to tap into the Baker McKenzie member firm’s international network and expand its IP portfolio
A team of partners that joined Boies Schiller Flexner say they would like to double the firm’s patent litigation capabilities
Gift this article